We’re here to help European citizens make sense of stem cells. We provide reliable, independent information and road-tested educational resources on stem cells and their impact on society. We're funded by the European Commission.
We’re here to help European citizens make sense of stem cells. We provide reliable, independent information and road-tested educational resources on stem cells and their impact on society. We're funded by the European Commission.
Watch award-winning short films on stem cell science, ethics and cell culture.
Featured
Inside the lab: Building the story
Fri, 20/01/2012 - 12:03pm — AnestisThe framework of a scientific story, which comprises a researcher’s vehicle to communicate personally-derived snippets of knowledge to colleagues, funders and the public, relies heavily on the choreographed assembly of data or “Results”. These are the building blocks of PhD theses, research articles, talks and grant proposals and thus hold an almost divine status in the minds and hearts of scientists. A “Result” can be anything: a number, a graph, an image, a statistical variation in a sea of data. It is the distillation of the empirical component of a researcher’s job, the visible product of manual work that, in the case of stem cell science, normally takes place inside laboratories and tissue culture hoods. Results are born out of questions and curiosity, both critical factors contributing to the design of a series of experiments aiming to shed light on the different facets of a hypothesis.
Ethics and reprogramming: do iPS cells solve the ethical dilemmas in stem cell research?
Like embryonic stem cells, hiPS cells are pluripotent - they can make all the different cell types of the body. Is the discovery of reprogramming technology a solution to the ethical issues faced by stem cell research? What new ethical dilemmas does the new technology bring with it? And should research on human embryonic stem cells continue, or should scientists now focus on hiPS cells instead?
Clinical trials news: January 2012 update
Fri, 13/01/2012 - 12:43pm — EmmaBefore new treatments can reach patients, they must be tested in clinical trials. This is our second brief update on some stem-cell-related trials currently under way or recently approved.
What's covered in this update?
This update looks at trials for amyotrophic lateral sclerosis (ALS) or motor neurone disease, as well as the latest news on how the trials we told you about in September are progressing. We’ve included details of one or two new trials for some of the conditions we focussed on last time: spinal injury, Stargardt’s macular dystrophy and stroke. We’ll post more updates on other themes in future, so tell us if there’s an area you really want to know about.